PHK
KIN

Point72 Hong Kong’s Kindred Biosciences, Inc. KIN Stock Holding History

Point72 Hong Kong’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-226
Closed -$2K – 1515
2019
Q1 		$2K Buy
+226
New +$2.29K ﹤0.01% 914

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Hong Kong's KIN Position: Q2 2019 in Review

Point72 Hong Kong sold out of Kindred Biosciences, Inc. (KIN) in Q2 2019, closing a stake of 226 shares — an estimated $2K sold.

Point72 Hong Kong first reported a position in KIN in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 75 funds tracked by Wall St. Rank hold KIN as of Q2 2019.

  • Point72 Hong Kong reported no remaining Kindred Biosciences, Inc. position as of Q2 2019 after selling out during the quarter.
  • Point72 Hong Kong sold 226 Kindred Biosciences, Inc. shares in Q2 2019, an estimated $2K.
  • Point72 Hong Kong first reported a position in Kindred Biosciences, Inc. in Q1 2019 and held it in 1 quarter.
  • Point72 Hong Kong's Kindred Biosciences, Inc. position peaked at $2K in Q1 2019.
  • 75 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2019.

Based on Point72 Hong Kong's 13F filing for Q2 2019, filed 14 Aug 2019.